WET AMD
Clinical trials for WET AMD explained in plain language.
Never miss a new study
Get alerted when new WET AMD trials appear
Sign up with your email to follow new studies for WET AMD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy shot could end monthly eye injections for wet AMD
Disease control OngoingThis Phase 3 trial tests a single injection of Ixo-vec gene therapy in 311 people with wet age-related macular degeneration (AMD). The goal is to see if it can maintain or improve vision as well as standard aflibercept injections, but with fewer follow-up treatments. Participants…
Matched conditions: WET AMD
Phase: PHASE3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Gene therapy could end frequent eye injections for wet AMD
Disease control OngoingThis study tests a one-time gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment aims to help the eye produce its own medicine to stop leaky blood vessels, potentially replacing the need for repeated eye injecti…
Matched conditions: WET AMD
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC